Lupin has entered into Business Transfer Agreement (BTA) with Lupin Life Sciences (LLSL) wholly owned subsidiary of the Company, to carve out, its trade generics business in India, as a going concern, on a slump sale basis. The said carve out will be effective from July 1, 2024.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
